CA
TCRR

Cliff Asness’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Cliff Asness’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-192,340
Closed -$531K – 2334
2022
Q1 		$531K Buy
192,340
+127,120
+195% +$400K ﹤0.01% 1798
2021
Q4 		$304K Buy
+65,220
New +$408K ﹤0.01% 1976

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.36B AUM 25.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Cliff Asness's TCRR Position: Q2 2022 in Review

Cliff Asness sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2022, closing a stake of 192,340 shares — an estimated $531K sold.

Cliff Asness first reported a position in TCRR in Q4 2021 and held it in 2 quarters. The position peaked at $531K in Q1 2022. 83 funds tracked by Wall St. Rank hold TCRR as of Q2 2022.

  • Cliff Asness reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Cliff Asness sold 192,340 TCR2 Therapeutics Inc. Common Stock shares in Q2 2022, an estimated $531K.
  • Cliff Asness first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • Cliff Asness's TCR2 Therapeutics Inc. Common Stock position peaked at $531K in Q1 2022.
  • 83 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2022.

Based on AQR Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.